True North Copper’s tenure across its Cloncurry and Mt Oxide Projects is located in the Mt Isa Inlier, which is home to a number of world-class mining projects focusing on copper and critical minerals development. The Bundarra Project was a project explored by Duke Exploration Limited and was acquired as part of the reverse-take-over process (RTO). The initial focus of True North Copper’s project development and production pipelines are the Cloncurry and Mt Oxide Projects.

Surefire Resources (ASX:SRN) is an Australian mineral exploration company based in Perth, Western Australia (WA). The company holds mineral exploration licences over Vanadium, Magnetite and Gold projects located in WA. Its focus is on adding value to shareholders by advancing its Victory Bore vanadium critical and battery minerals project, located close to existing infrastructure and currently in Pre-Feasibility stage. In addition, its large magnetite project with up to 1B tonnes of high grade Iron and its Gold project have potential to add considerable value to the company.

Prescient Therapeutics (ASX: PTX) is a clinical stage oncology company developing personalised medicine approaches to cancer, including targeted and cell therapies. Prescient’s universal CAR-T and targeted therapies are both personalised medicine approaches that seek to improve patient outcomes and provide new tools for clinicians in combating cancer.

Power Minerals Limited (ASX:PNN) is a diversified ASX-listed mineral resources exploration company focused on the systematic exploration and development of projects in demand-driven commodities. These include the Salta Lithium Brine Project in Argentina’s prolific lithium triangle, the Musgrave Nickel-Copper-Cobalt-PGE Project in northern South Australia’s Musgrave Province, and the Eyre Peninsula Kaolin-Halloysite Project on South Australia’s Eyre Peninsula.

ASAXS:3DP – Pointerra3D is a true end-to-end solution that stores, processes, manages, analyzes, extracts, visualizes and shares the key insights from massive 3D data at a new level of speed, smarts and scale. Pointerra’s patented cloud-deployed technology and Al-driven algorithms bring a new standard of speed, smarts, scale and on-demand access to the long-standing problem of being able to rapidly convert massive 3D point clouds and datasets into analytics and insights that provide definitive answers using digital twins to manage the physical world.

Neurizon Therapeutics (ASX:NUZ) clinical-stage biotechnology company developing new therapeutics for neurodegenerative diseases. The Company’s lead pipeline indication is targeting amyotrophic lateral sclerosis (ALS). ALS is the most common form of motor neurone disease (MND).
Neurizon has an extensive patent portfolio with multiple ‘methods of use’ patents granted and filed covering the use of NUZ-001 for the treatment of neurodegenerative diseases. The Company successfully completed a Phase 1 study of NUZ-001 in patients with ALS/MND with encouraging and robust results. At present, Neurizon anticipates commencing the following Phase 2/3 study in Q1 CY25.
The Company was formerly known as PharmAust Limited and changed its name to Neurizon Therapeutics Limited on 15 Oct 2024. The Company was listed on the ASX in Oct 2001.

Neurotech International (ASX:NTI) is a biopharmaceutical company focused on the development & commercialisation of neurological solutions that improve quality of life. NTI’s current focus is their world-first clinical study utilising NTI164 in the treatment for paediatric Autism Spectrum Disorder (ASD).

The Company is also focused on commercialising Mente, the world’s first home therapy that is clinically proven to increase engagement and improve relaxation in autistic children with elevated Delta band brain activity.

Lithium Universe (ASX: LU7) has a bold vision of building a Lithium resource and refinery facility in Canada that will provide the critical materials for batteries, helping the world transition towards cleaner energy. Lithium Universe is aiming to establish the Québec Lithium Processing Hub (QLPH). The QLPH is a major vertically integrated mine to battery grade lithium carbonate processing hub designed to feed the growing demand for lithium carbonate in the North American and European Battery Markets.

Lithium Plus Minerals (ASX: LPM) is a pure-play lithium company, with a tenement portfolio that lies adjacent to Core Lithium’s (ASX: CXO) Finniss Project – which sits in the northern end of the Litchfield Pegmatite Belt. This region has seen significant lithium mineralisation discoveries since 2017. The total area of Lithium Plus tenure exceeds 1690km2.

Lithium Plus has Multiple drill targets at the Lei, Cai, SW Cai, Perseverance and Jewellers projects offering excellent exploration potential to generate new targets and new lithium hosted discoveries. Exploration for lithium is the right commodity for the world’s transition to electric vehicles.

Lithium Plus has Multiple drill targets at the Lei, Cai, SW Cai, Perseverance and Jewellers projects that continue to offer excellent exploration potential to generate new targets and new lithium hosted discoveries. Exploration for lithium is the right commodity for the world’s transition to electric vehicles.

Island Pharmaceuticals is a drug research and repurposing company, focused on developing preventative or therapeutic drugs for viral infections.

We have a lead asset – ISLA-101 – that was initially developed by our wholly owned subsidiary, Isla Pharmaceuticals. ISLA-101 is a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases.

Dengue fever is the very definition of an unmet medical need. While 390 million humans are infected each year, it is thought that around 30-50% people with the disease do not present with symptoms, enabling the virus to spread within communities. Warming global climates are accelerating the presence of mosquito-borne viruses that can cause death to the US, Europe and Australia

There is no specific pharmaceutical treatment and the one vaccine which exists is available to a highly restricted audience.

Island has repurposed ISLA-101, an antiviral oral drug to treat mosquito-borne viruses (eg dengue fever / Zika) and is planning to move forward with Phase II studies with a significantly de-risked clinical program.